OTC Ads’ Vioxx Comparisons Communicate “Options,” Pitts Says
This article was originally published in The Tan Sheet
OTC analgesic ads comparing the pain relievers to Vioxx (rofecoxib) do not cross the boundary of propriety, according to Peter Pitts, senior VP-health affairs at the public relations firm Manning, Selvage & Lee (New York)
You may also be interested in...
A new website from Pfizer touting the firm's COX-2 pain reliever Celebrex (celecoxib) questions the perceived safety profile of over-the-counter drugs
Wyeth Consumer Health and McNeil are capitalizing on concerns generated by Merck's recall of its prescription pain reliever Vioxx with ads for Advil (ibuprofen) and Tylenol (acetaminophen)
OTC NSAID manufacturers could be the indirect beneficiaries of Merck's decision to initiate a worldwide recall of its COX-2 inhibitor Vioxx (rofecoxib)